Literature DB >> 8621380

Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities.

X Liu1, Q C Vega, R A Decker, A Pandey, C A Worby, J E Dixon.   

Abstract

The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in neural crest as well as kidney development. Genetic studies have demonstrated that germ line mutations in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease. However, despite the large body of genetic and biological evidence suggesting the importance of RET in development and neoplastic processes, the signal transduction mechanisms of RET remain unknown. To begin to understand the molecular mechanisms of the disease states caused by mutations in RET, the patterns of autophosphorylation of the wild-type RET and the MEN mutants were studied using site-directed mutagenesis and phosphopeptide mapping. Among the 6 autophosphorylation sites found in the wild-type RET receptor, the MEN2B mutant lacked phosphorylation at Tyr-1096, leading to decreased Grb2 binding, while simultaneously creating a new phosphorylation site. These changes in autophosphorylation suggest that the MEN2B mutation may result in the more aggressive MEN2B phenotype by altering the receptor's signaling capabilities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621380     DOI: 10.1074/jbc.271.10.5309

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

3.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.

Authors:  Anshuman Dixit; Ali Torkamani; Nicholas J Schork; Gennady Verkhivker
Journal:  Biophys J       Date:  2009-02       Impact factor: 4.033

4.  Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase.

Authors:  Maurice Perrinjaquet; Marçal Vilar; Carlos F Ibáñez
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

5.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Authors:  A Bardelli; P Longati; D Gramaglia; C Basilico; L Tamagnone; S Giordano; D Ballinari; P Michieli; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 6.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

Review 7.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

8.  Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis.

Authors:  Q C Vega; C A Worby; M S Lechner; J E Dixon; G R Dressler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 9.  Structure and physiology of the RET receptor tyrosine kinase.

Authors:  Carlos F Ibáñez
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 10.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.